Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. reports developments for a life sciences tools company whose primary business is conducted through Enzo Life Sciences. The business focuses on labeling and detection technologies from DNA to whole cell analysis, with products that include antibodies, genomic probes, assays, biochemicals, and proteins, and it monetizes its technology through product sales, global distribution, and licensing.
Company news commonly covers fiscal results, operating cash flow, EBITDA and Adjusted EBITDA measures, product and market-demand updates, cash dividends, debt repayment, governance changes, and the completed transfer of common stock trading from the NYSE to OTCQX under the symbol ENZB.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Enzo Biochem, a biosciences and diagnostics company, has scheduled a Special Meeting of Shareholders on May 22, 2023, to vote on the proposed sale of its clinical laboratory assets to Labcorp. The meeting will address the Asset Purchase Agreement dated March 16, 2023, which outlines the terms of the sale, including the assignment of certain liabilities. Shareholders are urged to vote by proxy before the meeting. The company has filed a proxy statement with the SEC detailing the transaction to inform shareholders adequately. Enzo Biochem is recognized for its innovative diagnostic technologies and holds a significant intellectual property portfolio.
Enzo Biochem (NYSE:ENZ) filed its Q2 FY23 report, revealing revenues of $16.3 million, marking a 52% decrease from $34.0 million in Q2 FY22 due to reduced COVID testing. The Clinical Labs segment contributed $8.8 million, a 63% decline year-over-year, while Enzo Life Sciences generated $7.5 million, stabilizing near Q2 FY22 levels. Notably, January 2023 saw the firm's second-highest monthly revenue in over a decade. The company entered an asset purchase agreement for its Clinical Labs assets, aiming to unlock shareholder value and optimize its remaining assets. No financial call was held for this quarter.